Browse life science companies in Stevenage, including organisations based within the Stevenage Bioscience Catalyst ecosystem.
Preclinical DMPK, bioanalysis and toxicology CRO
Pharmidex is a UK contract research organisation providing preclinical drug discovery and development services across DMPK, bioanalysis, toxicology, histology and in vitro ADME. Operating under GLP and GCP accreditation from its Hatfield facility, the company supports programmes in oncology, CNS, respiratory and…
Synthetic glycan-targeted small molecules for next-generation immunotherapy
Anomer Bio is a biotechnology company developing synthetic monosaccharides and small molecule drugs that target glycans, the sugars coating cell surfaces that influence immune responses and disease. Its platform combines multi-omics data and machine learning to model how cells process sugars, enabling the design of…
Specialist AAV vector manufacturer for gene therapy developers
Trisk Bio is a contract development and manufacturing organisation specialising in the production of adeno-associated virus vectors for gene therapy applications. Its intensified manufacturing processes use suspension bioreactors and chromatography-based purification to deliver high-purity AAV at scalable yields for…
Molecular biology enzymes and UK scientific reagent support
New England Biolabs (UK) is the British sales and technical-support subsidiary of New England Biolabs, supplying molecular biology reagents to research laboratories. Its catalogue includes restriction enzymes, DNA and RNA modifying enzymes, nucleic acid purification products, PCR reagents and sequencing library…
CDMO supplying custom reagents, antibodies, and diagnostic components
Life Science Group is an independent UK contract development and manufacturing organisation supplying custom cell culture media, sera, buffers, and reagents, alongside antibody generation services and diagnostic kit components. Operating from an ISO 9001 and ISO 13485 certified facility in Bedfordshire, the company…
RNA therapeutics platform targeting multiple disease pathways
SymphoRNA is a company developing RNA medicines designed to address complex diseases by targeting multiple biological pathways simultaneously. Its platform uses a polysaccharide-based delivery system to enable combination RNA therapies, with the aim of achieving outcomes that single-target approaches cannot. Spun out…
Novel mRNA technology platform for safer, faster vaccines
CamMed Therapeutics (Cambridge Medixine Ltd) is a preclinical biotechnology company developing a novel mRNA technology platform for vaccines and therapeutics. Inspired by natural biological phenomena, its engineered RNA molecules are designed to deliver safer, easier and faster medicines to the clinic while reducing…
VNAR antibody shuttles for brain-targeted biologic therapies
Ossianix is a biopharmaceutical company developing single-domain VNAR antibody platforms for targeted delivery of therapeutics across the blood-brain barrier. Its TXP1 shuttle binds transferrin receptor 1 to transport antibody-based medicines into the central nervous system. The company engineers antibody fusions and…
Host-response biomarker test to rapidly diagnose sepsis
Profionics is a diagnostics company developing a precision molecular test for rapid sepsis detection. Its platform analyses 52 patient-invariant biomarkers spanning inflammatory, metabolic, and adaptive immune pathways, using transcriptomics, metabolomics, and lipidomics in combination with artificial intelligence.…
Ion channel drug discovery platform for rare CNS disorders
Autifony Therapeutics is a clinical-stage UK biotech developing small molecule modulators of Kv3 voltage-gated potassium channels for rare genetic CNS disorders. Lead programmes target Fragile X syndrome and rare myoclonic epilepsy syndromes, with preclinical work extending to schizophrenia, hearing loss, and…
Antibody immunotherapy targeting toxic tau for neurodegenerative disease
TauC3 Biologics is a preclinical biopharmaceutical company developing an antibody-based immunotherapy that targets tauC3, a toxic, truncated form of the tau protein implicated in neurodegenerative disease. Its lead candidate, TBL-100, is a humanized monoclonal antibody developed with LifeArc, designed to selectively…
Cancer biotherapeutics targeting disease-specific protein isoforms
Isoform Oncology is an early-stage biotechnology company developing cancer therapeutics based on isoform switching and alternative RNA splicing. The company identifies cancer-specific protein variants arising from aberrant splicing and develops biotherapeutics designed to selectively target these disease-specific…